Discovery of the cancer cell selective dual acting anti-cancer agent...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted cancer therapy aims for selective cancer cell elimination but often causes side effects due to lack of mechanistic selectivity.
• Developing novel therapeutic agents with true mechanistic selectivity remains a critical challenge in oncology.

Purpose of the Study:

• To discover and characterize a novel agent, A131 (4a), with a dual mechanism of action for selective cancer targeting.
• To evaluate the efficacy and selectivity of A131 in preclinical cancer models.

Main Methods:

• Phenotypic screening identified A131 (4a) based on its effects on HeLa cells, including mitotic arrest and vesicle formation.
• Investigated A131's impact on key markers of mitosis (pH3) and autophagy (LC3).
• Conducted structure-activity relationship (SAR) studies and evaluated A131's antiproliferative activity against a panel of 30 cancer cell lines and in a mouse model.

Main Results:

• A131 (4a) demonstrated a dual mechanism, inhibiting both mitosis and autophagy, evidenced by increased pH3 and LC3 markers.
• The compound exhibited potent antiproliferative activity against 30 cancer cell lines with an average GI50 of 1.5 μM.
• A131 selectively induced cancer cell death while sparing normal cells, which regrew upon agent removal.
• In a paclitaxel-resistant colon cancer mouse model, A131 achieved 74% tumor growth inhibition at 20 mg/kg IP twice daily.

Conclusions:

• A131 (4a) represents a novel therapeutic agent with a unique dual mechanism targeting mitosis and autophagy.
• The dual inhibition of pH3 and LC3 markers is crucial for A131's selective cancer cell targeting and efficacy.
• A131 demonstrates significant potential as a targeted cancer therapy with improved selectivity and reduced toxicity.